Join to View Full Profile
250 25th Ave NSte 100Nashville, TN 37203
Phone+1 615-320-5090
Fax+1 615-320-1225
Are you Dr. Infante?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jeffrey Infante, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee and Georgia. He is a Director at Sarah Cannon.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Florida College of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2021 - 2027
TN State Medical License 2006 - 2022
Publications & Presentations
PubMed
- Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson
Targeted Oncology. 2022-09-01 - 10 citationsTranslational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson
Targeted Oncology. 2022-07-01 - 65 citationsPhase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook
Clinical Cancer Research. 2021-10-01
Press Mentions
Stand up to Cancer Announces Four Teams Focused on Diversity in Early Phase Cancer Clinical TrialsFebruary 8th, 2023- Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical TrialsMay 20th, 2022
Novel Interleukin-Based Immunotherapy Under Study in Pancreatic CancerDecember 29th, 2016- Join now to see all
